



**SOUTH CAROLINA REVENUE AND FISCAL AFFAIRS OFFICE**  
**STATEMENT OF ESTIMATED FISCAL IMPACT**  
(803)734-0640 • RFA.SC.GOV/IMPACTS

**Bill Number:** S. 0849  
**Author:** Cromer  
**Subject:** Generic prescription drugs  
**Requestor:** Senate Banking and Insurance  
**RFA Analyst(s):** Stein and Fulmer  
**Impact Date:** January 25, 2016

**Estimate of Fiscal Impact**

	<b>FY 2016-17</b>	<b>FY 2017-18</b>
<b>State Expenditure</b>		
General Fund	\$0	\$0
Other and Federal	\$0	\$0
Full-Time Equivalent Position(s)	0.00	0.00
<b>State Revenue</b>		
General Fund	\$0	\$0
Other and Federal	\$0	\$0
<b>Local Expenditure</b>	\$0	\$0
<b>Local Revenue</b>	\$0	\$0

**Fiscal Impact Summary**

This bill would have no expenditure impact on the General Fund, Federal Funds, or Other Funds.

**Explanation of Fiscal Impact**

**State Expenditure**

This bill amends Chapter 71, Title 38 relating to health insurance and benefits by adding Article 20 dealing with contracts between pharmacy benefits managers and pharmacists. The bill provides guidelines governing adjustments to the maximum allowable cost reimbursement for generic drugs paid by pharmacy benefits managers to pharmacists. The bill provides guidelines for appeals of the maximum allowable cost reimbursement to pharmacists set by pharmacy benefits managers.

Both the Department of Insurance and the Public Employee Benefits Authority report that this bill would have no expenditure impact on the General Fund, Federal Funds, or Other Funds.

**State Revenue**

N/A

**Local Expenditure**

N/A

**Local Revenue**

N/A

\_\_\_\_\_  
Frank A. Rainwater, Executive Director